This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Ketogenic Diet Therapy for Autism Spectrum Disorder

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2017 by Ryan Lee, MD, Shriners Hospitals for Children
Sponsor:
Collaborator:
University of Hawaii
Information provided by (Responsible Party):
Ryan Lee, MD, Shriners Hospitals for Children
ClinicalTrials.gov Identifier:
NCT02477904
First received: June 16, 2015
Last updated: February 28, 2017
Last verified: February 2017
  Purpose
This study will assess the effectiveness of the ketogenic diet (high-fat, low-carbohydrate, and moderate protein) in treating autism spectrum disorder (ASD). Three study groups will be comprised of children (2-21 years of age) based on whether or not they have ASD and receive the ketogenic diet - ASD/ketogenic diet, ASD/non-ketogenic diet, and non-ASD/non-ketogenic diet.

Condition Intervention
Autism Spectrum Disorder Other: Ketogenic Diet

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ketogenic Diet Therapy for Autism Spectrum Disorder

Resource links provided by NLM:


Further study details as provided by Ryan Lee, MD, Shriners Hospitals for Children:

Primary Outcome Measures:
  • Change from baseline in core symptoms of ASD [ Time Frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet) ]
    Assess core autistic symptoms through review/analysis of responses to the following measurement instruments: Autism Diagnostic Observation Schedule - Second Edition (ADOS-2); Asperger Syndrome Diagnostic Scale (ASDS); Childhood Autism Rating Scale (CARS-2); Gilliam Autism Rating Scale (GARS-3); Social Responsiveness Scale - Second Edition (SRS-2); Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) and DSM-V ASD criteria; standardized intelligence tests (if available, administered by child's school); and Vanderbilt ADHD Diagnostic Teacher Rating Scale Forms (Vanderbilt).


Secondary Outcome Measures:
  • Change from baseline in the number of medications used for ASD management [ Time Frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet) ]
    Assess changes through the review/analysis of self-report and medical record data.

  • Change from baseline in the dosage of medications used for ASD management [ Time Frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet) ]
    Assess changes through the review/analysis of self-report and medical record data.

  • Change from baseline in the number of lab tests ordered for ASD management [ Time Frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet) ]
    Assess changes through the review/analysis of self-report and medical record data.

  • Change from baseline in the number of emergency room or hospital visits for ASD management [ Time Frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet) ]
    Assess changes through review/analysis of self-report and medical record data.

  • Change from baseline in subject/family satisfaction with the ketogenic diet [ Time Frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet) ]
    Assess changes in subject/family satisfaction with the ketogenic diet through review/analysis of responses to a questionnaire.

  • Change from baseline in biochemical profiles due to the ketogenic diet [ Time Frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet) ]
    Assess biochemical profile differences and changes through the analysis of serum and urine ketone levels

  • Change from baseline in biochemical profiles due to the ketogenic diet [ Time Frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet) ]
    Assess biochemical profile differences and changes through the analysis of blood and stool (gut microbiome) specimen samples


Other Outcome Measures:
  • Possible effects of the ketogenic diet [ Time Frame: Post-ketogenic diet intervention ]
    Participants on the ketogenic diet will be followed clinically with standard of care until they are 21 years of age to examine the long-term benefits or risks of the KD.


Estimated Enrollment: 150
Study Start Date: March 2015
Estimated Study Completion Date: February 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ASD/KD
Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will receive the ketogenic diet (KD) intervention.
Other: Ketogenic Diet
Dietary
Other Names:
  • Classic Ketogenic Diet
  • Shriner's Ketogenic Diet
  • Non-Ketogenic Diet
Active Comparator: ASD/non-KD
Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
Other: Ketogenic Diet
Dietary
Other Names:
  • Classic Ketogenic Diet
  • Shriner's Ketogenic Diet
  • Non-Ketogenic Diet
Active Comparator: non-ASD/non-KD
Typically developing children (2-21 years of age) diagnosed as not having autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
Other: Ketogenic Diet
Dietary
Other Names:
  • Classic Ketogenic Diet
  • Shriner's Ketogenic Diet
  • Non-Ketogenic Diet

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   2 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Ages 2-21 years.
  • Primary diagnosis of autism spectrum disorder.
  • Parent/legal guardian and child able to read or understand English, and able/willing to provide informed consent/assent.
  • Females of childbearing potential must have a negative pregnancy test result and agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days after the last dose of study drug - childbearing potential is defined a girls who are > Tanner stage 2 and urine pregnancy tests are acceptable.

Exclusion Criteria:

  • Known cardiac disorder including arrhythmias or hypertension.
  • BMI < 3rd%ile.
  • Carnitine deficiency (primary).
  • Carnitine palmitoyltransferase (CPT) I or II deficiency.
  • Carnitine translocase deficiency.
  • Beta-oxidation defects - medium-chain acyl dehydrogenase deficiency (MCAD), long-chain acyl dehydrogenase deficiency (LCAD), short-chain acyld dehydrogenase deficiency (SCAD), long-chain 3-hydroxyacyl-coenzyme A (CoA) deficiency, and medium-chain 3-hydroxyacyl-CoA deficiency.
  • Pyruvate carboxylase deficiency.
  • Porphyria.
  • Inability to maintain adequate nutrition.
  • Patient or caregiver non-compliance.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02477904

Contacts
Contact: Miki Wong, RD 808-951-3726 mwong@shrinenet.org
Contact: Rob H Miyamoto, PhD 808-951-3693 rmiyamoto@shrinenet.org

Locations
United States, Hawaii
Shriners Hospitals for Children - Honolulu Recruiting
Honolulu, Hawaii, United States, 96826-1099
Contact: Miki Wong, RD    808-951-3726    mwong@shrinenet.org   
Contact: Rob H Miyamoto, PhD    808-951-3693    rmiyamoto@shrinenet.org   
Principal Investigator: Ryan W Lee, MD         
Sponsors and Collaborators
Shriners Hospitals for Children
University of Hawaii
Investigators
Principal Investigator: Ryan W Lee, MD Shriners Hospitals for Children - Honolulu
  More Information

Publications:

Responsible Party: Ryan Lee, MD, Director - Neurodevelopmental Clinic, Research, Shriners Hospitals for Children
ClinicalTrials.gov Identifier: NCT02477904     History of Changes
Other Study ID Numbers: HON1403
Study First Received: June 16, 2015
Last Updated: February 28, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Keywords provided by Ryan Lee, MD, Shriners Hospitals for Children:
Autism
Autism Spectrum Disorder
Ketogenic Diet
Biochemical Profiles

Additional relevant MeSH terms:
Disease
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Pathologic Processes
Neurodevelopmental Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 21, 2017